Huayuan Biopharma

Huayuan Biopharma is a clinical-stage biopharmaceutical company headquartered in Hangzhou, China, focused on the discovery and development of innovative small molecule therapeutics for metabolic and renal diseases. The company's lead candidate, HY-001, is a highly selective and potent URAT1 inhibitor currently in Phase 2 clinical development for the treatment of hyperuricemia and gout. Huayuan Biopharma aims to address significant unmet needs in nephrology by developing drugs that offer improved efficacy and safety profiles over current standards of care. Its pipeline also includes early-stage programs targeting chronic kidney disease and IgA nephropathy. The company is supported by a team of experienced drug discovery professionals and backed by leading venture capital investors in the life sciences sector.